

PA Criteria	Criteria Details						
Covered Uses (FDA approved indication)	<p>Ziextenzo is a leukocyte growth factor indicated to:</p> <ul style="list-style-type: none"> Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). <p>Ziextenzo is a biosimilar to Neulasta.</p>						
Exclusion Criteria	None.						
Required Medical Information	Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.						
Age Restriction	None.						
Prescriber Restrictions	None.						
Coverage Duration	One year. Dose will be approved according to the FDA approved labeling or within accepted standards of medical practice.						
Other Criteria/Information	<p>Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.</p> <table border="1"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>Q5120</td> <td>Ziextenzo Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg</td> <td>Billing unit: 0.5 mg 6 mg/0.6 mL SD syringe</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	Q5120	Ziextenzo Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg	Billing unit: 0.5 mg 6 mg/0.6 mL SD syringe
HCPCS	Description	Billing Units/How Supplied					
Q5120	Ziextenzo Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg	Billing unit: 0.5 mg 6 mg/0.6 mL SD syringe					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	5/15/2025	Pharmacy & Therapeutics (P&T) Committee	5/15/2025